{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:10:30Z","timestamp":1783012230311,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.jaad.2011.12.019","type":"journal-article","created":{"date-parts":[[2012,1,25]],"date-time":"2012-01-25T13:28:38Z","timestamp":1327498118000},"page":"623-629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up"],"prefix":"10.1016","volume":"67","author":[{"given":"Ziad","family":"Reguiai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Tabary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maizi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2011.12.019_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1172\/JCI114036","article-title":"Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases","volume":"83","author":"Stanley","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2011.12.019_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0065-2776(08)60503-9","article-title":"Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion","volume":"53","author":"Stanley","year":"1993","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jaad.2011.12.019_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2003.7","article-title":"Desmoglein as a target in autoimmunity and infection","volume":"48","author":"Amagai","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","article-title":"A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus","volume":"64","author":"Martin","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2010.02.052","article-title":"Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission","volume":"64","author":"Strowd","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archderm.1984.01650430127024","article-title":"Adjuvant therapy of pemphigus","volume":"120","author":"Bystryn","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0190-9622(96)80066-1","article-title":"Influence of treatment on the clinical course of pemphigus vulgaris","volume":"34","author":"Carson","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus: an update","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/archderm.138.9.1158","article-title":"Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris","volume":"138","author":"Sami","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib11","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2011.12.019_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2011.12.019_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0190-9622(79)80050-X","article-title":"Pemphigus and pemphigoid","volume":"1","author":"Lever","year":"1979","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2133.1999.02752.x","article-title":"Usefulness of enzyme linked immunosorbent assay using recombinant desmogleins 1 and 3 for the diagnosis of pemphigus","volume":"140","author":"Amagai","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2133.2002.04838.x","article-title":"Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3","volume":"147","author":"Cheng","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, endpoints and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2011.12.019_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaad.2011.12.019_bib19","first-page":"664","article-title":"Weaning of systemic steroid treatment in pemphigus: a twelve-year retrospective study on 270 French patients","volume":"13","author":"Stamm","year":"1995","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0190-9622(97)80127-2","article-title":"Sensitivity of indirect immunofluorescence, substrate specificity and immunoblotting in the diagnosis of pemphigus","volume":"37","author":"Jiao","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0190-9622(99)70183-0","article-title":"The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile","volume":"40","author":"Amagai","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1468-3083.2008.02715.x","article-title":"Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission","volume":"22","author":"Kwon","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2011.12.019_bib25","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab mediates a strong elevation of B-cell\u2013activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris","volume":"129","author":"Nagel","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1600-0625.2006.00499_1.x","article-title":"Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris or just \u2018witness of disease\u2019?","volume":"15","author":"Amagai","year":"2006","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib27","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1038\/jid.2008.330","article-title":"Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion","volume":"128","author":"Zambruno","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2011.12.019_bib28","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221102353X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221102353X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:22:55Z","timestamp":1759270975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221102353X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S019096221102353X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2011.12.019","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2011.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}